Marker Therapeutics (NASDAQ:MRKR) Issues Quarterly Earnings Results

Marker Therapeutics (NASDAQ:MRKR) posted its quarterly earnings data on Monday. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.14), Zacks reports. The firm had revenue of $1.22 million during the quarter, compared to analysts’ expectations of $5.25 million. Marker Therapeutics had a negative return on equity of 89.63% and a negative net margin of 179.74%.

Marker Therapeutics Price Performance

Marker Therapeutics stock traded down $0.09 during trading hours on Tuesday, reaching $1.14. The company had a trading volume of 119,212 shares, compared to its average volume of 58,826. Marker Therapeutics has a 12-month low of $1.10 and a 12-month high of $5.99. The company has a 50-day moving average price of $1.60 and a 200 day moving average price of $2.72.

Analyst Upgrades and Downgrades

MRKR has been the subject of a number of recent research reports. Brookline Capital Management upgraded Marker Therapeutics to a “strong-buy” rating in a research report on Monday, February 10th. Canaccord Genuity Group initiated coverage on shares of Marker Therapeutics in a research note on Wednesday, March 5th. They issued a “buy” rating and a $8.00 price objective for the company. Finally, WBB Securities reaffirmed a “strong-buy” rating and set a $12.50 target price on shares of Marker Therapeutics in a report on Tuesday.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.